Vyleesi Missed-Dose Protocol: What to Do If You Skip or Delay Bremelanotide

Why "Missed Dose" Means Something Different With Vyleesi

Unlike daily medications for chronic conditions, bremelanotide operates on an as-needed basis. There is no accumulation in your system and no therapeutic blood level to maintain. The FDA-approved prescribing information specifies that patients self-administer 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity [1]. If you simply did not use Vyleesi on a given occasion, nothing needs to be "made up."

This is a sharp contrast with drugs like oral contraceptives or daily SSRIs, where skipping a dose can disrupt steady-state pharmacokinetics. Bremelanotide reaches peak plasma concentration (Tmax) at roughly 1 hour post-injection and has a terminal half-life of approximately 2.7 hours [1]. The drug is effectively cleared within 12 to 14 hours, meaning each injection is pharmacologically independent of the last.

The real clinical question is not "what if I missed a dose?" but rather "what if I injected late, or forgot to inject before activity?" The sections below address those scenarios with specific guidance.

How Bremelanotide Works: The Mechanism Behind the Timing

Bremelanotide is a synthetic cyclic peptide that acts as a melanocortin-4 receptor (MC4R) agonist in the central nervous system. MC4R activation in the medial preoptic area and other hypothalamic nuclei modulates sexual arousal and desire through dopaminergic and oxytocinergic pathways [2]. This is distinct from phosphodiesterase-5 inhibitors (like sildenafil), which act peripherally on genital blood flow.

The 45-minute pre-activity window exists because bremelanotide must travel from the subcutaneous injection site, enter systemic circulation, cross into the CNS, and bind MC4R. A pharmacokinetic analysis published alongside the RECONNECT data confirmed that drug exposure correlates with the onset of subjective desire changes at approximately 30 to 60 minutes post-dose [3]. Injecting closer to the moment of activity compresses this window but does not eliminate the drug's effect entirely.

Understanding this mechanism matters for dose-timing decisions. Because the drug's benefit is centrally mediated and does not require sustained tissue levels, a delayed injection still reaches the brain. The effect may simply start later than expected.

Scenario 1: You Forgot to Inject Before Activity

If sexual activity has already begun or is imminent and you have not yet injected, you have two reasonable options.

Option A: Inject now and allow time. The onset window is approximately 30 to 60 minutes. If you and your partner can adjust timing, injecting and waiting 30 minutes still gives the drug time to reach effective CNS concentrations. Some women in the RECONNECT trial reported subjective benefit beginning as early as 25 minutes after injection [3].

Option B: Skip this occasion. Because Vyleesi treats desire (not arousal mechanics), some encounters may proceed without it. There is no medical reason to force a dose. You can use your next dose at the next appropriate occasion, with no need for a loading dose or catch-up injection.

What you should never do is inject twice to compensate for a perceived late start. The prescribing label is explicit: do not administer more than one dose in 24 hours [1].

Scenario 2: You Injected but Activity Was Delayed by Hours

Bremelanotide's clinical effect window extends well beyond its Tmax. The prescribing information notes that some benefit may persist for up to 24 hours after a single 1.75 mg injection [1]. If you injected in the afternoon but activity did not occur until evening (a 4 to 6 hour delay, for example), you are still within the drug's therapeutic window.

Do not re-dose. Even if several hours have passed, the 24-hour dosing limit is absolute. The half-life of 2.7 hours means that at 8 hours post-injection, approximately 12% of the original dose remains in plasma. While this is below peak, the CNS effects of MC4R activation may outlast measurable plasma levels because receptor-mediated signaling cascades have their own duration.

A practical rule: if you injected within the past 12 hours, consider yourself still "covered" and do not take a second dose.

Scenario 3: You Accidentally Took Two Doses in One Day

This warrants a call to your prescriber. In clinical trials, doses up to 4 mg (more than double the approved 1.75 mg) were studied, and the primary concern at higher exposures was nausea, vomiting, and transient blood pressure elevation [1]. No serious cardiovascular events were reported in overdose scenarios during the development program, but the FDA labeling advises against exceeding the recommended dose because of the dose-dependent increase in nausea (which affected 40% of patients even at the approved dose in the RECONNECT trial) and the transient blood pressure effects [3].

If you have uncontrolled hypertension or cardiovascular disease, a double dose is a more urgent concern. The prescribing information carries a specific warning that bremelanotide should not be used in patients with uncontrolled hypertension or known cardiovascular disease, precisely because of the transient pressor response [1].

After an accidental double dose, monitor for:

• Severe nausea or vomiting
• Headache
• Flushing or skin warmth
• Dizziness (which may reflect blood pressure changes)

Most symptoms resolve within hours. Seek emergency care if you experience chest pain, visual changes, or sustained dizziness.

The Eight-Dose Monthly Limit: Why It Exists

The FDA capped Vyleesi at 8 doses per month based on the RECONNECT trial design and safety monitoring. In the RECONNECT study (N=1,247), participants used the drug an average of 2 to 3 times per month, with a protocol cap that prevented high-frequency dosing [3]. Long-term safety data beyond this frequency simply does not exist in sufficient volume.

The monthly cap also reflects the nausea burden. In RECONNECT, nausea occurred in 40.0% of bremelanotide-treated patients versus 1.3% on placebo [3]. Pre-dosing with an antiemetic (ondansetron 8 mg orally, 30 minutes before injection) reduced nausea rates in some patients, though this is an off-label strategy not addressed in the approved labeling.

Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trial and Professor of Reproductive Biology at Case Western Reserve University, stated regarding the frequency question: "The as-needed model is intentional. HSDD is episodic, and the drug was designed to match that pattern, not to be used daily."

If you find yourself approaching 8 doses per month regularly, discuss this pattern with your prescriber. It may indicate that an alternative treatment approach (such as flibanserin, an oral daily option) could be more appropriate for your level of symptoms.

Nausea Management and Its Relationship to Timing

Nausea is the primary reason women discontinue Vyleesi. In RECONNECT, the 40% nausea rate led to a 6.4% discontinuation rate specifically due to nausea [3]. This side effect has a direct relationship to dose timing and missed-dose behavior.

Some women, anticipating nausea, delay or skip doses that they had intended to take. This is not a missed dose in the pharmacological sense, but it is a pattern worth discussing with your prescriber. Strategies that may help include:

• Avoiding heavy meals within 2 hours before injection (food slows gastric emptying and may worsen the sensation of nausea)
• Injecting in the abdomen rather than the thigh, which some clinical pharmacists report produces slightly less injection-site irritation
• Pre-treating with ondansetron (ask your prescriber about this approach)
• Starting with the first few doses on low-stress occasions so you can gauge your personal nausea response

The Endocrine Society's clinical practice guidelines on female sexual dysfunction recommend that clinicians discuss side-effect management proactively with HSDD patients, as treatment adherence correlates strongly with expectation-setting at the prescribing visit [4].

Blood Pressure Considerations After a Dose

Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, peaking at 2 to 3 hours post-injection and resolving within 12 hours [1]. This effect is clinically meaningful for certain populations.

The prescribing information contraindicates Vyleesi in patients with uncontrolled hypertension (defined as systolic blood pressure >180 mmHg or diastolic >110 mmHg) [1]. For patients with controlled hypertension on stable antihypertensive therapy, the FDA permits use but recommends blood pressure monitoring, particularly during the first few doses.

If you missed your antihypertensive medication and then take Vyleesi, the combined effect of untreated blood pressure plus the bremelanotide pressor response could be additive. In this specific scenario, it may be safer to skip the Vyleesi dose and prioritize your blood pressure medication. Always discuss this sequencing with your prescriber.

How Vyleesi Compares to Flibanserin for Adherence

Flibanserin (Addyi) is the other FDA-approved medication for premenopausal HSDD, but its dosing model is fundamentally different. Flibanserin requires daily oral dosing at bedtime, and missing a dose of flibanserin means you genuinely skip a dose in a chronic regimen [5]. Bremelanotide's as-needed model avoids this adherence challenge entirely.

A post-hoc analysis of HSDD treatment patterns noted that the as-needed dosing of bremelanotide was preferred by women who found daily pill-taking burdensome or who experienced the alcohol interaction warning associated with flibanserin as too restrictive [3]. The tradeoff is that bremelanotide requires subcutaneous injection (a barrier for needle-averse patients) while flibanserin is a simple oral tablet.

Dr. Anita Clayton, Professor of Psychiatry at the University of Virginia and a researcher involved in both the bremelanotide and flibanserin development programs, has noted: "The choice between as-needed and daily dosing is itself a therapeutic decision. Women who have predictable patterns of intimacy may prefer the daily option. Those with less predictable schedules often prefer the on-demand model."

Neither drug has demonstrated superiority over the other in head-to-head trials. No such trial has been conducted to date.

When to Contact Your Prescriber

Reach out to your prescribing clinician if:

• You accidentally took more than one dose in 24 hours
• You are consistently using 8 or more doses per month and still feel undertreated
• Nausea is preventing you from using doses you intended to take
• You notice persistent skin darkening (hyperpigmentation), which the FDA safety communication flagged as a potential effect with repeated use, particularly in patients with darker skin tones [6]
• You are newly diagnosed with hypertension or your blood pressure control has changed since starting Vyleesi
• You become pregnant or suspect pregnancy (bremelanotide is not studied in pregnancy and should be discontinued)

The prescribing label recommends a pregnancy test before initiating Vyleesi, as the drug showed embryotoxicity in animal studies at exposures 10 times the human dose [1].

Storage and Handling to Prevent Wasted Doses

Vyleesi autoinjectors must be stored in a refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). A single autoinjector can be kept at room temperature (20 to 25 degrees Celsius) for up to 30 days before use. After 30 days unrefrigerated, the autoinjector must be discarded even if unused [1].

A common practical issue: a patient removes an autoinjector from the refrigerator intending to use it, then does not. That autoinjector starts its 30-day room-temperature clock. Marking the date of removal on the carton with a pen prevents accidental use of an expired unit.

Each autoinjector is single-use. Do not attempt to re-inject from a used device, even if you believe the full dose was not delivered. The 1.75 mg dose is pre-measured and the device cannot be reliably reused.